Teva Pharmaceutical Industries Limited
TEVA
813 hedge funds and large institutions have $29.9B invested in Teva Pharmaceutical Industries Limited in 2016 Q2 according to their latest regulatory filings, with 57 funds opening new positions, 304 increasing their positions, 300 reducing their positions, and 76 closing their positions.
32% more call options, than puts
Call options by funds: $945M | Put options by funds: $717M
1% more repeat investments, than reductions
Existing positions increased: 304 | Existing positions reduced: 300
0% less capital inflows, than outflows
Capital inflows: $4.28B | Capital outflows: $4.3B
0.37% less ownership
Funds ownership: 58.65% → 58.28% (-0.37%)
3% less funds holding
Funds holding: 837 → 813 (-24)
23% less funds holding in top 10
Funds holding in top 10: 53 → 41 (-12)
25% less first-time investments, than exits
New positions opened: 57 | Existing positions closed: 76
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barrow, Hanley, Mewhinney & Strauss
Dallas,
Texas
|
+$713M |
| 2 |
PointState Capital
New York
|
+$356M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$305M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$234M |
| 5 |
Highfields Capital Management
Boston,
Massachusetts
|
+$211M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$510M |
| 2 |
Allianz Asset Management
Munich,
Germany
|
-$291M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$279M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$217M |
| 5 |
Paulson & Co
New York
|
-$204M |
TEVA Hedge Fund Activity: Q2 2016 in Review
813 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceutical Industries Limited (TEVA) for Q2 2016, worth a combined $29.9B — down 6.8% from $32.1B a quarter earlier.
Sellers outnumbered buyers: 76 funds closed out of TEVA and 57 opened new positions — a net loss of 19 holders — while 300 trimmed existing stakes and 304 added.
The largest buyer was Barrow, Hanley, Mewhinney & Strauss, adding an estimated $713M. The largest seller was Fidelity Investments, cutting an estimated $510M.
- 813 institutional investors held Teva Pharmaceutical Industries Limited (TEVA) as of Q2 2016, down from 837 in Q1 2016.
- Funds reported $29.9B of Teva Pharmaceutical Industries Limited stock for Q2 2016, down 6.8% quarter-over-quarter.
- 57 funds opened new Teva Pharmaceutical Industries Limited positions in Q2 2016 and 76 closed out, a net change of -19 holders.
- The largest Teva Pharmaceutical Industries Limited buyer in Q2 2016 was Barrow, Hanley, Mewhinney & Strauss, an estimated $713M added.
- The largest Teva Pharmaceutical Industries Limited seller in Q2 2016 was Fidelity Investments, an estimated $510M sold.
Based on aggregated 13F filings for Q2 2016.